BBA
MTNB icon

Baader Bank Aktiengesellschaft’s Matinas BioPharma MTNB Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21
Closed -$2.05K – 509
2024
Q2 		$2.05K Buy
+21
New +$2.85K ﹤0.01% 420
2023
Q4 		– Sell
-45
Closed -$3.77K – 371
2023
Q3 		$3.77K Buy
45
+28
+165% +$5.16K ﹤0.01% 304
2023
Q2 		$3.5K Buy
+17
New +$5.95K ﹤0.01% 391

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Sanctuary Advisors
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Baader Bank Aktiengesellschaft's MTNB Position: Q3 2024 in Review

Baader Bank Aktiengesellschaft sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 21 shares — an estimated $2.05K sold.

Baader Bank Aktiengesellschaft first reported a position in MTNB in Q2 2023 and held it in 3 quarters. The position peaked at $3.77K in Q3 2023. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Baader Bank Aktiengesellschaft reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 21 Matinas BioPharma shares in Q3 2024, an estimated $2.05K.
  • Baader Bank Aktiengesellschaft first reported a position in Matinas BioPharma in Q2 2023 and held it in 3 quarters.
  • Baader Bank Aktiengesellschaft's Matinas BioPharma position peaked at $3.77K in Q3 2023.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2024, filed 29 Oct 2024.